Nathan Goodyear, MD, MD(H)

3.1K posts

Nathan Goodyear, MD, MD(H) banner
Nathan Goodyear, MD, MD(H)

Nathan Goodyear, MD, MD(H)

@drgoodyear

Nathan Goodyear is a author, speaker, physician, and works with Dr Jason Williams at the Williams Cancer Institute. https://t.co/87HnEKiACo

Scottsdale, AZ Katılım Haziran 2009
1K Takip Edilen1.9K Takipçiler
Nathan Goodyear, MD, MD(H)
Nathan Goodyear, MD, MD(H)@drgoodyear·
Senescent cells release inflammatory signals that promote tumor growth. Reference: SenoVax™ study on senescent cell immunization
English
1
0
19
957
Nathan Goodyear, MD, MD(H)
Nathan Goodyear, MD, MD(H)@drgoodyear·
Old, dysfunctional cells don’t just age the body—they support disease.
English
1
0
24
1K
Nathan Goodyear, MD, MD(H)
Nathan Goodyear, MD, MD(H)@drgoodyear·
New research shows targeting senescent cells can reduce tumor growth. Reference: Reduction of solid tumors by senescent cell immunization (SenoVax™)
English
1
0
17
870
Nathan Goodyear, MD, MD(H)
Nathan Goodyear, MD, MD(H)@drgoodyear·
@rgergelymd The medical system exists for but one reason—serve the patient. The quicker all of medicine remembers that the better. Medicine is best served local.
English
0
1
2
20
Robert Gergely, MD
Robert Gergely, MD@rgergelymd·
@drgoodyear x.com/rgergelymd/sta…
Robert Gergely, MD@rgergelymd

The President is passionately advocating for a groundbreaking plan to decentralize medical records, empowering patients to take ownership and control of their own data. A recent poll shows that an overwhelming 72.6% of Americans are in favor of this vital change. With @CMSGov and @Droz at the forefront, and @AmyGleason47 tasked with executing the President's vision, we have the opportunity for real transformation. Yet, the entrenched electronic health record (EHR) industry is clinging to the status quo, resisting progress. They are misusing Amy's position to undermine the President's initiative by pushing new gadgets while keeping the centralized system intact—this directly opposes the intended policy. This is a clear manifestation of the deep state working against the interests of the American people! @POTUS @SusieWiles47 @Scavino47 @SecKennedy .

QME
1
0
1
11
Nathan Goodyear, MD, MD(H)
Nathan Goodyear, MD, MD(H)@drgoodyear·
Identifying problems and innovation in solutions are the result of being a physician and a scientist. It will bring the future of care to today.
Jason R. Williams, MD, DABR@jasonwilliamsmd

Dr. Paul Savage is describing what we see every week in the clinic. PFAS, plastics, pesticides, and mycotoxins damage DNA and reprogram the gut microbiome. Microbiome diversity is one of the strongest predictors of whether a patient will respond to immunotherapy. The patients walking in today have less of it than we used to see.

English
1
0
10
1K
Nathan Goodyear, MD, MD(H)
Nathan Goodyear, MD, MD(H)@drgoodyear·
At WCI, we don’t just treat tumors—we address the environment around them.
English
1
0
14
1K
Williams Cancer Institute
Williams Cancer Institute@WmsCInstitute·
Tomorrow on The GoodWill Show — Friday, 1 PM PST @drgoodyear and @jasonwilliamsmd on three studies worth your time: -PEF ablation + intratumoral immunotherapy for liver cancer -A new Nature paper mapping obesity's hidden damage to the immune system and nervous system -Vitamin C as a nitrosation inhibitor across diets and water quality Real science. Real implications. Live on X.
Williams Cancer Institute tweet media
English
3
2
43
3.1K
Nathan Goodyear, MD, MD(H)
Nathan Goodyear, MD, MD(H)@drgoodyear·
Early immune signals like PD-1 and TIGIT can predict resistance to therapy. Reference: Spatial predictors of response to chemo-immunotherapy in MSS colorectal cancer
English
1
0
10
1.1K
Nathan Goodyear, MD, MD(H) retweetledi
Jason R. Williams, MD, DABR
Jason R. Williams, MD, DABR@jasonwilliamsmd·
At SITC last November we presented a case of head and neck squamous cell carcinoma treated with PEF ablation plus intratumoral immunotherapy. Full response, no toxicity. Our paper in next month's Journal of Immunotherapy reports the same approach in advanced hepatocellular carcinoma. Two of three patients with durable responses, one at 3.5 years post with a complete radiologic response. Tumor thrombus regressed. No high-grade toxicities. The platform is reproducing across tumor types. With Dr. Nathan Goodyear and the WCI team.
Jason R. Williams, MD, DABR tweet mediaJason R. Williams, MD, DABR tweet media
English
6
8
40
19.5K
Nathan Goodyear, MD, MD(H)
Nathan Goodyear, MD, MD(H)@drgoodyear·
Visibility without access isn’t enough. The immune system must recognize AND reach the tumor.
English
1
0
20
620
Nathan Goodyear, MD, MD(H)
Nathan Goodyear, MD, MD(H)@drgoodyear·
Increasing tumor mutations can make cancer more visible to the immune system—but only if immune cells can reach it. Reference: MAYA trial findings on MSS colorectal cancer
English
1
0
11
799
Nathan Goodyear, MD, MD(H)
Nathan Goodyear, MD, MD(H)@drgoodyear·
More immune cells + better access = better outcomes. Cancer treatment is not just about killing cells—it’s about enabling the immune system.
English
1
0
12
986

Keşfet

@rgergelymd @WmsCInstitute @jasonwilliamsmd @elonmusk @BarackObama @taylorswift13 @cristiano @BillGates